Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis.
Stratmann JA, Timalsina R, Atmaca A, Rosery V, Frost N, Alt J, Waller CF, Reinmuth N, Rohde G, Saalfeld FC, von Rose AB, Acker F, Aspacher L, Möller M, Sebastian M. Stratmann JA, et al. Among authors: atmaca a. Ther Adv Med Oncol. 2022 Jun 4;14:17588359221097191. doi: 10.1177/17588359221097191. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35677321 Free PMC article.
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer.
Althoff FC, Schäfer LV, Acker F, Aguinarte L, Heinzen S, Rost M, Atmaca A, Rosery V, Alt J, Waller CF, Reinmuth N, Rohde G, Saalfeld FC, Becker von Rose A, Möller M, Frost N, Sebastian M, Stratmann JA. Althoff FC, et al. Among authors: atmaca a. Front Oncol. 2023 Sep 22;13:1273478. doi: 10.3389/fonc.2023.1273478. eCollection 2023. Front Oncol. 2023. PMID: 37810988 Free PMC article.
Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer.
Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N, Lerbs W, Hecker D, Sehouli J, Knuth A, Jager E. Al-Batran SE, et al. Among authors: atmaca a. Oncology. 2006;70(2):141-6. doi: 10.1159/000093005. Epub 2006 Apr 26. Oncology. 2006. PMID: 16645327 Clinical Trial.
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
Al-Batran SE, Pauligk C, Wirtz R, Werner D, Steinmetz K, Homann N, Schmalenberg H, Hofheinz RD, Hartmann JT, Atmaca A, Altmannsberger HM, Jäger E. Al-Batran SE, et al. Among authors: atmaca a. Ann Oncol. 2012 Jul;23(7):1699-705. doi: 10.1093/annonc/mdr552. Epub 2011 Nov 23. Ann Oncol. 2012. PMID: 22112973 Free article.
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.
Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, Banat AG, Brueck P, Caca K, Prasnikar N, Kullmann F, Günther Derigs H, Koenigsmann M, Dingeldein G, Neuhaus T, Jäger E. Atmaca A, et al. Br J Cancer. 2013 Feb 5;108(2):265-70. doi: 10.1038/bjc.2012.555. Epub 2013 Jan 17. Br J Cancer. 2013. PMID: 23329236 Free PMC article. Clinical Trial.
194 results